Baker Bros. Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
|
|||||
|
2022
Q1 | $63.5M | Hold |
|
|||||
|
2021
Q4 | $57.7M | Hold |
|
|||||
|
2021
Q3 | $64.9M | Hold |
|
|||||
|
2021
Q2 | $65.9M | Hold |
|
|||||
|
2021
Q1 | $65.8M | Hold |
|
|||||
|
2020
Q4 | $64.9M | Hold |
|
|||||
|
2020
Q3 | $65.1M | Sell |
|
|||||
|
2020
Q2 | $111M | Sell |
|
|||||
|
2020
Q1 | $107M | Sell |
|
|||||
|
2019
Q4 | $135M | Sell |
|
|||||
|
2019
Q3 | $128M | Hold |
|
|||||
|
2019
Q2 | $119M | Buy |
|
|||||
|
2019
Q1 | $96.8M | Buy |
|
|||||
|
2018
Q4 | $52.2M | Sell |
|
|||||
|
2018
Q3 | $116M | Hold |
|
|||||
|
2018
Q2 | $92.8M | Hold |
|
|||||
|
2018
Q1 | $78.3M | Sell |
|
|||||
|
2017
Q4 | $77.9M | Buy |
|
|||||
|
2017
Q3 | $37.8M | Hold |
|
|||||
|
2017
Q2 | $28.4M | Sell |
|
|||||
|
2017
Q1 | $38.8M | Hold |
|
|||||
|
2016
Q4 | $34.7M | Hold |
|
|||||
|
2016
Q3 | $45.3M | Hold |
|
|||||
|
2016
Q2 | $40.7M | Hold |
|
|||||
|
2016
Q1 | $35.4M | Buy |
|
|||||
|
2015
Q4 | $48.1M | Buy |
|
|||||
|
2015
Q3 | $29.9M | Buy |
|
|||||
|
2015
Q2 | $25.9M | Hold |
|
|||||
|
2015
Q1 | $21.5M | Sell |
|
|||||
|
2014
Q4 | $12.4M | Hold |
|
|||||
|
2014
Q3 | $8.69M | Hold |
|
|||||
|
2014
Q2 | $8.23M | Buy |
|
|||||
|
2014
Q1 | $7.21M | Buy |
|